Search clinical trials for: Amyvid

Total 47 results

University Hospital, Angers

Not yet recruiting

Impact of a History of Tonsillectomy or Adenoidectomy on the Severity of COVID-19 : AMYVID Study

COVID-19 | Tonsillectomy | Adenoidectomy
Universidad Central del Caribe
University of Puerto Rico

Not yet recruiting

B-amyloid as a Marker for GBM Bioimaging

Glioblastoma

Puerto Rico
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Invicro

Recruiting

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

Alzheimer Disease

United States
Brain Health Alliance

Recruiting

Entire-body PET Scans for Multiple Sclerosis (EPSMS)

Multiple Sclerosis

United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Medical College of Wisconsin

Terminated

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Cardiac Amyloidosis

United States
Elisa Konofagou
National Institute on Aging (NIA)

Active, not recruiting

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Brigham and Women's Hospital

Terminated

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Cardiac Amyloidosis

United States
Institute for Neurodegenerative Disorders
Biogen

Completed

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Multiple Sclerosis

United States
The Cleveland Clinic
Avid Radiopharmaceuticals

Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis

United States
Northwestern University

Completed

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia (PPA)

Dementia | Alzheimer Disease | Primary Progressive Aphasia

United States
University of Pittsburgh

Completed

Return of Amyloid Imaging Results (RAISR Study) (RAISR)

Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Samuel Gandy

Completed

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

Traumatic Brain Injury | Mild Cognitive Impairment | Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals
Eli Lilly and Company; PRA Health Sciences

Completed

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Alzheimer Disease | Cognition Disorders

United States
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Brigham and Women's Hospital
Boston University; U.S. Army Medical Research and Development Command

Completed

Tau Imaging of Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Completed

Florbetapir Calibration to the Centiloid Scale

Alzheimer's Disease

United States, Australia
Molecular NeuroImaging
Roche Pharma AG; Institute for Neurodegenerative Disorders

Completed

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Alzheimer's Disease (AD)

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Alzheimer's Disease (AD) | Tauopathies | Parkinson's Disease (PD) | Progressive Supranuclear Palsy (PSP) | Chronic Traumatic Encephalopathy (CTE) | Frontal Temporal Dementia (FTD) | Pick's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals

Completed

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States

Search clinical trials for: Amyvid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations